Sepio Capital 13F: Exits Eli Lilly and (LLY) Stake
Key Points
- Sepio Capital closed its position in Eli Lilly and Company LLY by selling all 826 shares reported in its filing on October 22, 2026.
- Other institutional investors adjusted their holdings, with Symphony Financial raising its stake to 7,802 shares and Perigon Wealth Management reducing its position.
- Eli Lilly and Company trades around $1,306.74, backed by a strong trailing revenue of $79.67 billion and an upcoming earnings report on October 29, 2026.
Get Eli Lilly and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $LLY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
Sepio Capital closed out its position in Eli Lilly and Company LLY by selling all 826 shares it previously held. The complete exit appeared in a Form 13F filing with the U.S. Securities and Exchange Commission on October 22, 2026.
LLY
Eli Lilly and Company
What Changed in Sepio Capital's Eli Lilly Position
Sepio Capital sold its entire stake of 826 shares during the period, bringing its holdings down to zero shares. The previous quarter showed the fund holding 826 shares of the drug maker.
Other Institutional Activity in Eli Lilly and Company
Other fund managers made mixed adjustments to their Eli Lilly holdings during the filing period. Symphony Financial grew its holdings by 1,205 shares, ending with 7,802 shares worth about $9,191,438. Strategic Blueprint lowered its stake by 785 shares, leaving it with 12,911 shares valued at about $14,938,745. True North Advisors grew its position by 1,108 shares to hold 4,217 shares worth roughly $4,879,120. Midwest Trust added 5,069 shares, finishing with 73,312 shares valued at approximately $84,827,891. Perigon Wealth Management trimmed 10,705 shares, closing out the quarter with 26,608 shares worth about $30,786,964.
Eli Lilly and Company Stock Up 1.8%
Eli Lilly shares recently traded around $1,306.74 as of October 23, 2026, roughly equal to the closing price of $1,306.69 on the October 22 filing date. The stock trades well above both its 50-day and 200-day moving averages and sits just below its 52-week high of $1,311.75.
Recent Earnings
Eli Lilly reported trailing-twelve-month revenue of $79.67 billion alongside earnings of $29.79 per share. The company posted a net profit margin of 33.5% and a return on equity of 102.3%.
Dividend
Eli Lilly pays an annual dividend rate of $6.92 per share, translating to a dividend yield of 0.54% with a payout ratio of 21.7%.
Insider Buying and Selling at Eli Lilly and Company
Company insiders completed several stock sales ahead of the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00 for a total value of $5,950,000. Officer Donald A. Zakrowski sold 2,000 shares on August 10, 2026, at $1,185.01 per share totaling $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at $1,175.10 per share for a total value of $7,638,150.
Analysts Set New Price Targets
Wall Street firms updated their views on Eli Lilly ahead of the filing period. JP Morgan maintained its overweight rating with a price target of $1,500.00 on September 28, 2026. Morgan Stanley kept an overweight rating and lifted its target to $1,430.00 on October 7, 2026. Cantor Fitzgerald maintained an overweight rating with a target of $1,440.00 on October 8, 2026. RBC Capital reiterated an outperform rating with a $1,500.00 target on October 12, 2026. Leerink Partners maintained an outperform rating and raised its target to $1,316.00 on October 21, 2026. The stock holds a consensus buy rating from analysts with a mean price target of $1,331.55 across 30 opinions.
About Eli Lilly and Company
Eli Lilly and Company creates medicines that treat serious health conditions globally. The company focuses on areas such as diabetes, oncology, immunology, and neuroscience, helping patients manage complex diseases.
Bottom Line
Investors will look toward Eli Lilly's upcoming earnings report on October 29, 2026, for further updates on financial performance.
Related Filing Alerts
Source: Sepio Capital's 13F filing on $LLY (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts